InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,772.20
(
-0.19%
)
Post# of 2795
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 2016

Tuesday, 05/09/2017 7:11:45 PM

Tuesday, May 09, 2017 7:11:45 PM

Post# of 2795
OCRX presents additional post-hoc data from STOP-HE trial—reports 1Q17 results:

http://ir.ocerainc.com/releasedetail.cfm?releaseid=1025649

I think OCRX has a fair—but not great—chance of persuading the FDA to endorse advancing OCR-002 to phase-3, using the kind of trial design proposed on today's CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up